CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.

about

CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.

Item

http://www.wikidata.org/entity/Q38821274

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

CYP3A4 genotype is associated ...... h preserved ejection fraction.

@en

type

Item

label

CYP3A4 genotype is associated ...... h preserved ejection fraction.

@en

prefLabel

CYP3A4 genotype is associated ...... h preserved ejection fraction.

@en

P1476

CYP3A4 genotype is associated ...... h preserved ejection fraction.

@en

P2093

D L Mann

http://www.w3.org/2001/XMLSchema#string

G S Huggins

http://www.w3.org/2001/XMLSchema#string

I Mongrain

http://www.w3.org/2001/XMLSchema#string

J L Rouleau

http://www.w3.org/2001/XMLSchema#string

M-P Dubé

http://www.w3.org/2001/XMLSchema#string

N L Pereira

http://www.w3.org/2001/XMLSchema#string

R Fouodjio

http://www.w3.org/2001/XMLSchema#string

S H Shah

http://www.w3.org/2001/XMLSchema#string

S de Denus

http://www.w3.org/2001/XMLSchema#string

T P Cappola

http://www.w3.org/2001/XMLSchema#string

P2860

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Principal components analysis corrects for stratification in genome-wide association studies

Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

P2888

tpj.2017.8

P31

scholarly article

P356

10.1038/TPJ.2017.8

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085052597

http://www.w3.org/2001/XMLSchema#string

P698

28440343

http://www.w3.org/2001/XMLSchema#string

P932

5656562

http://www.w3.org/2001/XMLSchema#string